J S Heier

Summary

Affiliation: Ophthalmic Consultants of Boston
Country: USA

Publications

  1. ncbi request reprint Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration: year 1 results of the FOCUS Study
    Jeffrey S Heier
    Ophthalmic Consultants of Boston, Boston, MA 02114, USA
    Arch Ophthalmol 124:1532-42. 2006
  2. doi request reprint Neovascular age-related macular degeneration: individualizing therapy in the era of anti-angiogenic treatments
    Jeffrey S Heier
    Vitreoretinal Service, Ophthalmic Consultants of Boston, Boston, Massachusetts Electronic address
    Ophthalmology 120:S23-5. 2013
  3. doi request reprint Ranibizumab for choroidal neovascularization secondary to causes other than age-related macular degeneration: a phase I clinical trial
    Jeffrey S Heier
    Ophthalmic Consultants of Boston, Boston, Massachusetts, USA
    Ophthalmology 118:111-8. 2011
  4. doi request reprint Vitreous nonsteroidal antiinflammatory drug concentrations and prostaglandin E2 levels in vitrectomy patients treated with ketorolac 0.4%, bromfenac 0.09%, and nepafenac 0.1%
    Jeffrey S Heier
    Ophthalmic Consultants of Boston, Boston, Massachusetts 02114, USA
    Retina 29:1310-3. 2009
  5. doi request reprint Pathology beyond neovascularization: new targets in age-related macular degeneration
    Jeffrey S Heier
    Ophthalmic Consultants of Boston, Boston, Massachusetts 02114, USA
    Retina 29:S39-41. 2009
  6. ncbi request reprint Ketorolac versus prednisolone versus combination therapy in the treatment of acute pseudophakic cystoid macular edema
    J S Heier
    Ophthalmic Consultants of Boston, Boston, Massachusetts, USA
    Ophthalmology 107:2034-8;discussion 2039. 2000
  7. ncbi request reprint Effects of ranibizumab on exudative disciform scars
    Fatima K Ahmad
    Harvard Medical School, Boston, Massachusetts, USA
    Ophthalmic Surg Lasers Imaging 40:366-72. 2009
  8. ncbi request reprint Ranibizumab for treatment of neovascular age-related macular degeneration: a phase I/II multicenter, controlled, multidose study
    Jeffrey S Heier
    Ophthalmic Consultants of Boston, Boston, Massachusetts 02114, USA
    Ophthalmology 113:633.e1-4. 2006
  9. doi request reprint Pseudoexfoliation: High risk factors for zonule weakness and concurrent vitrectomy during phacoemulsification
    Bradford J Shingleton
    Center for Eye Research and Education, Boston, Massachusetts 02114, USA
    J Cataract Refract Surg 36:1261-9. 2010
  10. ncbi request reprint A pilot study of multiple intravitreal injections of ranibizumab in patients with center-involving clinically significant diabetic macular edema
    Dal W Chun
    Ophthalmic Consultants of Boston, Boston, Massachusetts 02114, USA
    Ophthalmology 113:1706-12. 2006

Collaborators

Detail Information

Publications20

  1. ncbi request reprint Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration: year 1 results of the FOCUS Study
    Jeffrey S Heier
    Ophthalmic Consultants of Boston, Boston, MA 02114, USA
    Arch Ophthalmol 124:1532-42. 2006
    ....
  2. doi request reprint Neovascular age-related macular degeneration: individualizing therapy in the era of anti-angiogenic treatments
    Jeffrey S Heier
    Vitreoretinal Service, Ophthalmic Consultants of Boston, Boston, Massachusetts Electronic address
    Ophthalmology 120:S23-5. 2013
    ..In this Interview, Jeffrey S. Heier, MD, of Ophthalmic Consultants of Boston, Massachusetts, discusses his approaches to managing the treatment of patients with AMD and providing them with individualized care...
  3. doi request reprint Ranibizumab for choroidal neovascularization secondary to causes other than age-related macular degeneration: a phase I clinical trial
    Jeffrey S Heier
    Ophthalmic Consultants of Boston, Boston, Massachusetts, USA
    Ophthalmology 118:111-8. 2011
    ..To investigate the safety and efficacy of ranibizumab for the treatment of choroidal neovascularization (CNV) secondary to causes other than age-related macular degeneration (AMD)...
  4. doi request reprint Vitreous nonsteroidal antiinflammatory drug concentrations and prostaglandin E2 levels in vitrectomy patients treated with ketorolac 0.4%, bromfenac 0.09%, and nepafenac 0.1%
    Jeffrey S Heier
    Ophthalmic Consultants of Boston, Boston, Massachusetts 02114, USA
    Retina 29:1310-3. 2009
    ..To assess vitreous concentrations of nonsteroidal antiinflammatory drugs (NSAIDs) and prostaglandin E(2) in patients treated with NSAIDs before vitrectomy...
  5. doi request reprint Pathology beyond neovascularization: new targets in age-related macular degeneration
    Jeffrey S Heier
    Ophthalmic Consultants of Boston, Boston, Massachusetts 02114, USA
    Retina 29:S39-41. 2009
    ....
  6. ncbi request reprint Ketorolac versus prednisolone versus combination therapy in the treatment of acute pseudophakic cystoid macular edema
    J S Heier
    Ophthalmic Consultants of Boston, Boston, Massachusetts, USA
    Ophthalmology 107:2034-8;discussion 2039. 2000
    ..0% ophthalmic solution, and ketorolac and prednisolone combination therapy in the treatment of acute, visually significant, cystoid macular edema (CME) occurring after cataract extraction surgery...
  7. ncbi request reprint Effects of ranibizumab on exudative disciform scars
    Fatima K Ahmad
    Harvard Medical School, Boston, Massachusetts, USA
    Ophthalmic Surg Lasers Imaging 40:366-72. 2009
    ..To evaluate the effect of intravitreal ranibizumab in patients with leaking disciform scars...
  8. ncbi request reprint Ranibizumab for treatment of neovascular age-related macular degeneration: a phase I/II multicenter, controlled, multidose study
    Jeffrey S Heier
    Ophthalmic Consultants of Boston, Boston, Massachusetts 02114, USA
    Ophthalmology 113:633.e1-4. 2006
    ..To assess safety of repeated intravitreal injections of ranibizumab in treating neovascular age-related macular degeneration (AMD), and to assess changes in visual acuity (VA) and AMD lesion characteristics...
  9. doi request reprint Pseudoexfoliation: High risk factors for zonule weakness and concurrent vitrectomy during phacoemulsification
    Bradford J Shingleton
    Center for Eye Research and Education, Boston, Massachusetts 02114, USA
    J Cataract Refract Surg 36:1261-9. 2010
    ..To assess the frequency and results of cataract surgery with concurrent vitrectomy due to zonule weakness in eyes with pseudoexfoliation (PXF)...
  10. ncbi request reprint A pilot study of multiple intravitreal injections of ranibizumab in patients with center-involving clinically significant diabetic macular edema
    Dal W Chun
    Ophthalmic Consultants of Boston, Boston, Massachusetts 02114, USA
    Ophthalmology 113:1706-12. 2006
    ..To evaluate the biologic activity of multiple intravitreal injections of ranibizumab in patients with center-involving clinically significant diabetic macular edema (DME) and to report any associated adverse events...
  11. ncbi request reprint Innovative treatments for exudative age-related macular degeneration
    Rubin W Kim
    Ophthalmic Consultants of Boston, MA 02114, USA
    Int Ophthalmol Clin 44:41-50. 2004
  12. ncbi request reprint Visual prosthetic device for bilateral end-stage macular degeneration
    Dal W Chun
    Ophthalmic Consultants of Boston, Tufts New England Eye Center, 50 Staniford Street, Suite 600, Boston, MA 02114, USA
    Expert Rev Med Devices 2:657-65. 2005
    ..This was accompanied by a clinically significant improvement in quality of life...
  13. ncbi request reprint Preoperative visual acuity as a prognostic indicator for laser treatment of macular edema due to branch retinal vein occlusion
    Manju L Subramanian
    Ophthalmic Consultants of Boston, USA
    Ophthalmic Surg Lasers Imaging 37:462-7. 2006
    ....
  14. ncbi request reprint Multiple laser treatments for macular edema attributable to branch retinal vein occlusion
    Erica Esrick
    Ophthalmic Consultants of Boston, Boston, Massachusetts 02114, USA
    Am J Ophthalmol 139:653-7. 2005
    ..To report the visual outcome of multiple laser treatments for macular edema attributable to branch retinal vein occlusions (BRVO) and to determine if any prognostic factors exist for improvement...
  15. ncbi request reprint Tolerability and efficacy of multiple escalating doses of ranibizumab (Lucentis) for neovascular age-related macular degeneration
    Philip J Rosenfeld
    Bascom Palmer Eye Institute, Department of Ophthalmology, University of Miami, Miami, Florida 33136, USA
    Ophthalmology 113:623.e1. 2006
    ....
  16. ncbi request reprint Preferential Hyperacuity Perimeter (PreView PHP) for detecting choroidal neovascularization study
    Yair Alster
    Clin Reg Consulting Services Inc, Irvine, California, USA
    Ophthalmology 112:1758-65. 2005
    ....
  17. ncbi request reprint Ranibizumab versus verteporfin for neovascular age-related macular degeneration
    David M Brown
    Vitreoretinal Consultants, Methodist Hospital, Houston, TX 77030, USA
    N Engl J Med 355:1432-44. 2006
    ....
  18. ncbi request reprint Ranibizumab for neovascular age-related macular degeneration
    Philip J Rosenfeld
    Bascom Palmer Eye Institute, Department of Ophthalmology, University of Miami Miller School of Medicine, Miami, FL 33136, USA
    N Engl J Med 355:1419-31. 2006
    ..Ranibizumab--a recombinant, humanized, monoclonal antibody Fab that neutralizes all active forms of vascular endothelial growth factor A--has been evaluated for the treatment of neovascular age-related macular degeneration...
  19. ncbi request reprint Implantable miniature telescope for the treatment of visual acuity loss resulting from end-stage age-related macular degeneration: 1-year results
    Henry L Hudson
    Retina Centers, Tucson, Arizona, USA
    Ophthalmology 113:1987-2001. 2006
    ..To evaluate the safety and efficacy of an implantable visual prosthetic device (IMT; VisionCare Ophthalmic Technologies, Saratoga, CA) in patients with bilateral, end-stage age-related macular degeneration (AMD)...